United Therapeutics reported a positive Phase 3 outcome for ralinepag and said it will pursue an FDA filing this year. The company linked the once-daily candidate to a substantial reduction in clinical worsening events in pulmonary arterial hypertension (PAH), positioning a potential launch in 2027. The Phase 3 results cited a 55% drop in risk of clinical worsening in the trial cohort, a hard clinical endpoint regulators prioritize in PAH approvals. United Therapeutics (corporate filings and company release) framed the result as a pivotal efficacy readout that supports a near-term regulatory submission. PAH is a progressive disease marked by high pulmonary artery pressure and right-heart strain; clinical-worsening endpoints typically bundle mortality, hospitalization and symptomatic decline. The company’s plan to file this year will shift investor focus to regulatory timelines and label expectations.